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Abstract
Background: The extent to which smoking contributes to adverse outcomes among men and women of all ages
undergoing dialysis is uncertain. The objective of this study was to determine the differential impact of smoking on
risks of mortality and kidney transplantation by age and by sex at dialysis initiation.
Methods: We conducted a population-based cohort of incident U.S dialysis patients (n = 1, 220, 000) from 1995–2010.
Age- and sex-specific mortality and kidney transplantation rates were determined for patients with and without a
history of cardiovascular disease. Multivariable Cox regression evaluated relative hazard ratios (HR) for death and kidney
transplantation at 2 years stratified by atherosclerotic condition, smoking status and age. Analyses were adjusted for
demographic characteristics, non-cardiovascular conditions, laboratory variables, socioeconomic and lifestyle factors.
Results: The average age was 62.8 (±15) years old, 54 % were male, and the majority was white. During 2-year
follow-up, 40.5 % died and 5.7 % were transplanted. Age- and sex-specific mortality rates were significantly higher
while transplantation rates were significantly lower for smokers with atherosclerotic conditions than non-smokers
(P < 0.01). The adjusted mortality hazards were significantly higher for smokers with pre-existing coronary disease
(HR 1.15, 95 % CI (1.11–1.18), stroke (HR 1.21, 1.16–1.27) and peripheral vascular disease (HR = 1.21, 1.17–1.25) compared
to non-smokers without these conditions (HR 1.00, referent group). The magnitude of effect was greatest for younger
patients than older patients. Contrastingly, the adjusted risks of kidney transplantation were significantly lower for
smokers with coronary disease: (HR 0.60, 0.52–0.69), stroke; (HR 0.47, 0.37–0.60), and peripheral arterial disease
(HR 0.55, 0.46–0.66) respectively compared to non-smokers without these conditions.
Conclusions: We provide compelling evidence that smoking is associated with adverse clinical outcomes and
reduced lifespans among dialysis patients of all ages and sexes. The adverse impact is greatest for younger men
and women.
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Background
A diagnosis of end-stage kidney disease (ESKD) is asso-
ciated with reduced life expectancy with mortality rates
of 20 % at 1-year and a 5-year survival of 30 % in US pa-
tients [1]. Atherosclerotic cardiovascular disease is a
major contributor to mortality and accounts for over
60 % of all–causes of death [1]. The prevalence of coron-
ary disease, stroke and peripheral arterial disease is high
at dialysis initiation and each condition contributes inde-
pendently to total and cardiovascular mortality [2–8].
The extent to which these conditions contribute to ele-
vated death risk is determined by the effectiveness of
cardiovascular treatment strategies and the degree to
which existing atherosclerotic risk factors are controlled
[7, 8, 9]. Despite these facts, it is surprising that only few
studies exist that have addressed the clinical significance
of smoking, an established modifiable risk factor, on
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clinical outcomes among patients with ESKD, [10–15].
The evidence to date would suggest that smoking among
patients who require dialysis is associated with accelerated
atherosclerosis and increased mortality. Furthermore, pa-
tients who smoke prior to kidney transplantation experi-
ence higher rates of graft loss, cardiovascular events and
death [16–20].
Smoking is a well-established cause of excess mortality
in the general population [21, 22]. It is a highly addictive
behavior and remains the greatest risk factor for athero-
sclerotic disease in the developed world [23]. The extent
to which smoking contributes to excess mortality in
men and in women on dialysis with and without pre-
existing atherosclerotic disease has not been fully ex-
plored. It is unclear for example whether continued
smoking at dialysis initiation exerts greater impact on
individuals with pre-existing coronary disease, peripheral
vascular disease and stroke compared to patients with-
out these conditions. It is equally uncertain whether and
to what extent smoking alters the risk of receiving a kid-
ney transplant among patients with pre-existing athero-
sclerotic conditions. Finally, there are few studies to our
knowledge that have examined in detail the impact of
smoking across age and sex groups. A better under-
standing of the hazards of smoking among these high-
risk patients would help inform health policy and lend
support for more aggressive smoking intervention strat-
egies prior to and after the onset of renal replacement
therapy.
The aim of this study was to 1) explore the relative
contribution of smoking with mortality among new dia-
lysis patients with and without atherosclerotic cardiovas-
cular disease, and 2) to examine the association of
smoking with likelihood of kidney transplantation taking
into consideration differences in demographic, comorbid
characteristics and 3) to determine whether associations
with these outcomes differed between men and women
and across representative age groups.
Methods
Data
Our hypotheses were tested in a historical prospective
cohort of all incident dialysis patients from May 1995
and December 2008 using data from the U.S. Renal Data
System [1]. This registry collects information on all pa-
tients who undergo dialysis or kidney transplantation in
the United States. Data on demographic details, comor-
bid conditions, lifestyle factors, laboratory values and
dates of dialysis initiation were captured on the Center
for Medicare and Medicaid Services (CMS) Medical Evi-
dence Form, which is completed for all patients at dialy-
sis initiation [24]. Smoking status was recorded as
current tobacco use at dialysis initiation. The following
variables were included for our analyses: age, gender,
race, the presence or absence of coronary artery disease,
peripheral arterial disease, stroke, diabetes, hypertension,
congestive heart failure, chronic lung disease, malig-
nancy, alcohol use, drug dependence, inability to ambu-
late and transfer independently, current employment
status, and pre-dialysis use of erythropoietin. Laboratory
data included serum creatinine measured at or prior to
dialysis initiation and serum albumin. Body mass index
(BMI) was estimated from recorded weight and height
measurements and residual renal function at dialysis ini-
tiation was estimated from estimated glomerular filtra-
tion rate (eGFR) using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) [25].
Cohort assembly
An observational cohort was assembled using the stand-
ard analysis files (SAF) of the US Renal Data System.
The Medical Evidence File (SAF.Medevid, n =1,753,496),
Mortality file (SAF.Patients, n = 2,377,166), and the
Treatment history file (SAF.Rxhist90, n = 13,038,727)
were merged by unique patient identity number. Patients
were excluded if; there was unknown data on race, sex,
cause of ESKD; date of first treatment occurred before
May 1995; medical evidence forms were completed prior
to 5/1/1995 or after 12/31/2010, and if age < 18 and >
100 years and leaving a sample of 1,445,980 patients. In
addition, we further restricted the sample to the period
5/1/1995- 12/31/2008 to ensure a minimum of 2 years
follow-up on all participants leaving 1,220, 000 patients
in the final study cohort.
Statistical analysis
The prevalence and distribution of coronary disease, per-
ipheral arterial disease and stroke, by smoking status
was compared for the entire incident population. Com-
parisons between groups were conducted using the chi-
square and t-tests. Multivariate logistic regression
explored the independent relationships of demographic,
clinical, laboratory, lifestyle variables and elements of
pre-dialysis care with current smoking status and associ-
ations were represented by adjusted odds-ratios (AOR)
and 95 % confidence intervals (CI).
Two-year mortality rates were calculated for subjects
with and without each atherosclerotic condition strati-
fied by smoking status. Poisson regression compared
mortality rates while Cox regression modeled survival
times for each condition stratified by smoking status.
The study start date was defined as the date of first
regular dialysis and patients were followed until the
earliest of death, kidney transplantation, loss to follow-
up, end of 2 years, or December 2010. Unadjusted and
adjusted hazard ratios (HR) were calculated and models
of increased complexity were constructed to explore the
conjoint associations of each condition and smoking
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status with mortality. In the final model, we adjusted for
a comprehensive set of clinical, laboratory, lifestyle,
functional, and pre-dialysis factors. Interactions between
smoking and each atherosclerotic condition were tested
for in the multivariable Cox model with a P-value <0.01
determined as significant. In addition, we specifically
tested for effect modification of age on the association of
smoking status with each primary outcome. Stratum-
specific hazards ratios were determined for each sub-
group for significant interactions. The proportionality of
the Cox model was tested by assessing Shoenfield resid-
uals and time-covariate interactions. Finally, all analyses
were repeated with date of first kidney transplant as the
major outcome and death as a censoring variable. Statis-
tical analysis was performed using SAS statistical soft-
ware (version 9.3, SAS institute, Cary, NC, USA).
Results
Baseline characteristics
The study cohort included 1, 220, 000 individuals who
commenced dialysis between May 1995 and December
2008 and followed until December 2010. The mean age
of subjects was 62.7 years, 54 % were male, and the ma-
jority was white. Subjects with atherosclerotic conditions
were on average younger, male, black, diabetic, had
higher prevalence of chronic lung disease, drug and alco-
hol use, and a higher percentage of patients reporting
difficulty with walking and transferring independently
(Tables 1 and 2). Younger age, non –white race, most
cardiovascular conditions, drug and alcohol dependence
were significantly associated with smoking at dialysis ini-
tiation (Additional file 1: Table S1). Patients age 18 to
40 years and 50 to 60 years were between 8–11 times
more likely to smoke compared to those age > 80 years.
Drug and alcohol dependence were also significantly as-
sociated with smoking while employment was inversely
related. The model had good discrimination with a C-
statistic of 78 %.
Death rates among patients with atherosclerotic disease
at dialysis initiation by smoking status
The overall mortality at 2 years was significantly higher
in smokers with pre-existing atherosclerotic conditions
than non-smokers. Age-specific mortality rates for
coronary disease, stroke and peripheral arterial disease
were significantly higher for smokers than non-smokers
and this pattern was consistent for men and women
(Additional file 2: Figure S1a-c, Additional file 3: Figure
S2a-c). The conjoint associations of coronary disease
and smoking status with mortality are illustrated in
Table 3. The interaction between smoking and coronary
disease with 2-year mortality was significant (P <0.01).
Compared to non-smokers without coronary disease
(referent HR 1.00), the demographic-adjusted HR for
death was significantly higher for smokers without dis-
ease HR 1.26 (1.24–1.28) and greatest for smokers with
coronary disease HR 1.50 (1.47–1.53). In the fully ad-
justed model, patients with coronary disease who contin-
ued to smoke experienced the greatest mortality risks
HR 1.14 (1.10–1.17). On further examination, we found
that the interaction between coronary disease and smok-
ing with mortality was further modified by age and this
was confirmed when a 3-way interaction term with age
was included in the model. The HR of smoking on mor-
tality was significantly greater for younger than older pa-
tients (Fig. 1), and the magnitude of the effect increased
progressively for younger patients.
For stroke patients, the mortality pattern was similar
to those with coronary disease (P < 0.01 for the inter-
action). Mortality risks were significantly higher for
stroke patients who continued to smoke compared to
those who did not with adjustment for demographic
characteristics [HR 1.53 (1.49–1.58) versus HR 1.32
(1.31–1.33)] versus the referent category (HR = 1.00).
The association was attenuated but remained significant
in the fully adjusted model. Similarly, the relationship of
smoking status with mortality among stroke patients
also varied according to age (Fig. 2) with the greatest
hazards of death present for younger patients. For pa-
tients with peripheral arterial disease, the pattern of as-
sociation was similar to those described above although
the interaction term was not significant (Fig. 3).
Transplant rates among patients with atherosclerotic
disease at dialysis initiation by smoking status
Age-specific transplant rates for coronary disease, stroke
and peripheral vascular diseases were significantly lower
for patients who smoked than those who did not and
this pattern was consistent for men and women
(Additional file 4: Figure S3a-3c, Additional file 5: Figure
S4a-4c). For patients with coronary disease, transplant
rates were significantly lower for younger patients who
smoked than those who did not. For example among
men age 20–40, transplantation rates were 45 per 1000
person-years for smokers versus 88 per 1000 person
years for non-smokers. With advancing age, this dispar-
ity narrowed as overall rates between groups decreased
significantly.
The associations of coronary disease with transplant-
ation for smokers and non-smokers are shown in Table 4.
Compared to the referent (non-smokers without coron-
ary disease), the demographic adjusted-HR for trans-
plantation was lowest among patients with coronary
disease who continued to smoke, HR 0.36 (0.33–0.40).
In the fully adjusted model, patients with coronary dis-
ease who continued to smoke experienced the lowest
risk of transplantation HR 0.61 (0.53–0.69). The risk as-
sociations for patients with stroke or peripheral vascular
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Table 1 Baseline Characteristics of Overall Population and of Patients with and without Coronary Disease by Smoking Status
Coronary Artery Disease No Coronary Disease
Overall Smoking Status Smoking Status
Yes No Yes No
(n = 19,271) (n = 295,192) 49,459 856,020
Demographics
Age (years) 62.8 (15.3) 63 (11.3) 69.6 (11.2)* 54.3 (13.8) 60.9 (15.9)*
Gender (%)
Male 54.3 66.5 57.9* 63.3 52.3*
Race (%)
White 65.4 77.3 77.6 59.9 61.2*
Black 29.7 20.3 18.4* 37.4 33.4*
Asian 3.8 1.1 2.9* 1.5 4.3*
Native American 1.11 1.3 1* 1.2 1.2
Hispanic (%)
Hispanic 7.8 2.8 6.6* 3 8.6*
Comorbid Conditions (%)
Diabetes (cause of ESKD)a 45.3 45.3 53.5* 33.3 43.2*
Diabetes (as comorbid condition) 52.8 55.3 62.9* 40.4 50*
Hypertension 79.4 88.8 83.8* 84 77.4*
Heart Failure 33.1 57.3 59.2* 24.2 24.1
Coronary Disease 25.8
Stroke 9.5 20.8 16.2* 8.9 7*
Peripheral Arterial Disease 14.7 43.2 30.8* 13.4 8.5*
Chronic lung disease 8.2 41.2 13* 18.7 5.1*
Malignancy 6.4 7.6 7.3 6.4 6
Body Mass Index (kg/m2) 27.5 (7.3) 26 (6.7) 27.3 (6.9)* 26.1 (7.1) 27.7 (7.5)*
Lifestyle factors (%)
Alcohol Dependence 1.5 6.1 0.7* 10.6 1.2*
Drug dependence 1.2 2.7 0.3* 8.6 1*
Functional Status (%)
Inability to walk independently 5.2 8.2 8 4.4 4.2
Inability to transfer independently 2.1 2.6 3.2* 1.4 1.8*
Employment Status (%)
Full time employment 8.2 4.5 3.4* 9.7 9.8
Part time employment 1.8 1.4 1.1* 2.2 2*
Unemployed 19.8 16.6 11.5* 31.1 22*
Homemaker 4.8 3.5 5.2* 3 4.9*
Retired from age 39.8 39.1 55.6* 20.8 35.4*
Retired from disability 19.4 29.7 18.9* 26.5 18.9*
Medical leave of absence 3.0 2.4 1.4* 4.3 3.5*
Student 0.29 0.03 0.02 0.2 0.4*
Other 3.0 2.6 2.7 2.2 3.1*
Laboratory Variables
Serum Creatinine (μmol/L) 654.2 (309.4) 601.7 (251.4) 560.9 (226.4)* 726.3 (351.9) 681.2 (330.4)*
eGFRb (ml/min/1.73 m2) 8.6 (3.8) 8.8 (3.7) 8.8 (3.6) 8.0 (3.8) 7.9 (3.6)*
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disease according to smoking status followed a similar
pattern. For stroke patients, transplantation risks were
significantly poorer among those who continued to
smoke compared to those who did not adjusting for
demographic factors HR 0.50 (0.40-0.63) versus the ref-
erent category. Similarly, for patients with peripheral ar-
terial disease, this pattern of association was virtually
identical HR 0.57 (0.48–0.67).
Discussion
In this national study, we report associations of smoking
with higher rates of death and lower rates of kidney
transplantation in a contemporary cohort of dialysis pa-
tients. Smoking at dialysis initiation was associated with
excess mortality for both men and women with and
without pre-existing cardiovascular disease. Although
these risks were present for patients of all ages, they
were greatest among younger patients who started dialy-
sis and continued into old age. Although continued
smoking was associated with several known mortality
predictors, adjustment for these factors did not abolish
the risk. Smoking was equally detrimental to kidney
transplantation among men and women with athero-
sclerotic cardiovascular disease. These findings demon-
strate that smoking remains a substantial, yet modifiable,
contributor to overall poor outcomes for men and
women of all ages at dialysis initiation both directly from
high death rates and indirectly from low rates of kidney
transplantation.
The present study sheds new light on the mortality
risks of continued smoking among those with and with-
out atherosclerotic disease at dialysis initiation. These
risks were substantial such that continued smoking con-
ferred on average an additional 25 % higher death risk
for patients with stroke, coronary disease or peripheral
arterial disease. The following observations are note-
worthy and highlight the importance of smoking as a
major mortality risk factor in dialysis cohorts. First,
smoking increased the risk of death for all patients with
newly diagnosed ESKD regardless of disease status.
Second, the highest risk groups in each category were
those patients who had known coronary disease,
stroke and peripheral arterial disease and who contin-
ued to smoke. Third, the pattern of risk was similar
for men and women but was greatest for younger dia-
lysis patients and continued right into old age without
exception. These findings suggest that patients with
atherosclerotic disease and who continue to smoke
following dialysis experience a greatly magnified risk
of death beyond the risk that associated with dialysis
and co-existing comorbidity.
What is striking from this analysis is the extent to
which smoking increased mortality risks across all repre-
sentative age and sex groups, an observation which has
not been previously demonstrated [13]. From the youn-
gest to the oldest patients, in men and in women, mor-
tality rates were significantly higher in smokers than
non-smokers and the pattern was consistent for each
major condition. The negative impact of smoking on
mortality was present in young adults age 18–40, and
continued right into older age > 70 years without excep-
tion. Our analysis uncovered a very strong age effect in
that the mortality impact of smoking was greatest
among younger patients than older patients. Although
this is not surprising as younger patients are less likely
to have competing mortality risks compared with older
patients, it nevertheless reinforces the concept that
smoking remains a substantial modifiable factor among
young patients who reach ESKD. Equally important, the
elevated mortality associated with smoking was carried
into old age and the magnitude of the risk was similar to
other established mortality predictors including malnu-
trition and chronic lung disease. These findings would
suggest that smoking cessation programs should be pur-
sued for all smokers, irrespective of age, who approach
ESKD.
A key objective of this study was to define the associ-
ation of smoking with hazards of kidney transplantation.
Table 1 Baseline Characteristics of Overall Population and of Patients with and without Coronary Disease by Smoking Status
(Continued)
Albumin (g/L) 31 (7.0) 31 (6.6) 31.3 (6.4)* 3.1 (0.7) 3.1 (0.7)*
Pre-ESRD Care (%)
Erythropoietin use 29.0 27.4 32.2* 23.2 28.3*
Dialysis Modality at day 90 (%)
Peritoneal Dialysis 7.0 6.5 5.3* 7.9 7.5
Hemodialysis 80.4 79.6 78.7 81.4 80.9
All values are reported as % or means with standard deviation
aESKD: end-stage kidney disease
bGlomerular filtration rate (ml/min per 1.73 m2) was based on the Chronic Kidney Disease Epidemiology Collaboration [25]
*P < 0.001 for all bivariate comparisons
58 patients from the original cohort of 1, 220, 000 had missing data leaving 1, 219, 942 patients
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Table 2 Characteristics of patients with and without Stroke and Peripheral Arterial Disease by Smoking Status at dialysis initiation
Stroke No Stroke Peripheral Arterial Disease No Peripheral Arterial Disease
Smoking Status Smoking Status Smoking Status Smoking Status
Yes No Yes No Yes No Yes No
(n = 8,384) (n = 107, 806) 60,339 1,043,406 (n = 14, 960) (n = 163, 846) 53,763 987,379
Demographics
Age (years) 61.9 (11.7) 68.4 (12)* 56 (13.8) 62.6 (15.5)* 63.1 (11.3) 68.1 (11.9)* 55 (13.8) 62.3 (15.7)*
Gender (%)
Male 63.3 52.5* 64.3 53.9* 65.4 57.9* 63.9 53.1*
Race (%)
White 69.1 66.2* 64.2 65.3* 79 76.2* 60.9 63.6*
Black 28.6 29.5 33.1 29.6* 18.8 20.3* 36.4 31.1*
Asian 1.1 3.3* 1.4 4* 0.8 2.1* 1.6 4.2*
Native American 1.3 0.9 1.2 1.1 1.4 1.4 1.2 1.1
Hispanic (%)
Hispanic 2.3 5.8* 3.1 8.3* 2.8 7.2* 3 8.2*
Comorbid Conditions (%)
Diabetes (cause of ESKD)a 44 52.1* 35.6 45.2* 48.5 59.4* 33.4 43.5*
Diabetes (comorbid condition) 54 61.8* 43.3 52.4* 57.9 68* 40.9 50.9*
Hypertension 91.1 87.2* 84.5 78.2* 89.7 85.8* 84.1 77.9*
Heart Failure 45 46.8 31.9 31.7 52 56.9* 28.3 29.1*
Coronary Disease 47.7 44.3* 25.3 23.7* 55.6 55.4 20.4 20.7
Stroke 22.4 19.5* 9.4 7.7*
Peripheral Arterial Disease 40 29.6* 19.2 12.6*
Chronic lung disease 35.7 11.9* 23.5 6.7* 43.6 14.2* 19.8 6*
Malignancy 8 7.3 6.5 6.2 7.4 6.1* 6.5 6.4
Body Mass Index (kg/m2) 25.5 (6.6) 26.8 (6.8)* 26.2 (7) 27.7 (7.4)* 25.6 (6.7) 27.4 (7.3)* 26.2 (7) 27.6 (7.4)*
Lifestyle factors (%)
Alcohol Dependence 8.2 1.0* 9.5 1.1* 6.1 0.8* 10.3 1.1*
Drug dependence 4.2 0.6* 7.4 0.8* 2.7 0.4* 8.2 0.9*
Functional Status (%)
Inability to walk independently 11.5 13.6* 4.6 4.3* 11.3 11.9 3.8 4
Inability to transfer independently 4.3 6.5* 1.4 1.7* 3.5 4.8* 1.2 1.7*
Employment Status (%)
Full time employment 3 2.2* 9 8.8 4 3.1* 9.4 9*
Part time employment 0.8 0.7 2.2 1.9* 1.4 1* 2.2 1.9*
Unemployed 19.6 14.1* 28.1 19.9* 16.1 13.3* 30.1 20.3*
Homemaker 3.6 5* 3.1 4.9* 3.6 4.9* 3 4.9*
Retired from age 35.8 51.2* 24.6 39.5* 39.3 51.3* 22.2 38.8*
Retired from disability 33 23.3* 26.6 18.5* 31.2 22.3* 26.4 18.4*
Medical leave of absence 1.9 1.2* 4 3.1* 2 1.3* 4.3 3.2*
Student 0.05 0.05 0.1 0.3* 0.03 0.04 0.2 0.3*
Other 2.3 2.4 2.3 3.1* 2.4 2.7 2.3 3.1*
Laboratory Variables
Serum Creatinine (μmol/L) 616 (259) 580 (244)* 702 (340) 658 (317)* 594 (248) 564 (228)* 719 (347) 665 (321)*
eGFRb (ml/min/1.73 m2) 8.7 (3.7) 8.6 (3.6) 8.1 (3.8) 8.1 (3.7)* 8.9 (3.8) 8.9 (3.7) 8 (3.8) 8 (3.6)
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In this analysis, we provide evidence that smoking was
associated with lower likelihood of transplantation but
disproportionately more so for those with atherosclerotic
conditions. Smoking may reduce the likelihood of kidney
transplantation either due to worsening of existing
comorbidity or due to the development of de-novo
smoking-related comorbidity while on dialysis. In sup-
port, we found that smokers at dialysis initiation were
far more likely to have several comorbid medical condi-
tions and adverse lifestyle profiles. Our findings extend
the observations of Sandhu et al. who found that smok-
ing was associated with reduced rates of kidney
Table 2 Characteristics of patients with and without Stroke and Peripheral Arterial Disease by Smoking Status at dialysis initiation
(Continued)
Albumin (g/L) 30.7 (6.7) 30.9 (6.6) 3.1 (0.7) 3.1 (0.7)* 30.6 (6.8) 30.7 (6.6) 3.1 (0.7) 3.2 (0.7)*
Pre-ESRD Care (%)
Erythropoietin use pre-dialysis 25.6 30.1* 24.2 29.2* 28.2 32.7* 23.3 28.7*
Dialysis Modality at day 90 (%)
Peritoneal Dialysis 5.9 4.5* 7.7 7.2* 6.2 4.9* 7.8 7.3*
Hemodialysis 80.4 79.8 81 80.4* 79.5 79.2 81.3 80.6*
All values are reported as % or means with standard deviation
aESKD: end-stage kidney disease
bGlomerular filtration rate (ml/min per 1.73 m2) was based on the Chronic Kidney Disease Epidemiology Collaboration [25]
*P < 0.001 for all bivariate comparisons
Table 3 Hazards Ratios (HR) for Death for each Atherosclerotic Condition by Smoking Status among new dialysis Patientsa
With Coronary Disease Without Coronary Disease
Group Smokers Non-smokers Smokers Non-smokers
HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Referent
Unadjusted 1.55 (1.52–1.58) 1.65 (1.64–1.66) 0.96 (0.95–0.98) 1.00
Demographic-adjustedb 1.50 (1.47–1.53) 1.25 (1.25–1.26) 1.26 (1.24–1.28) 1.00
Adjusted for all covariatesc 1.14 (1.11–1.17) 1.10 (1.09–1.11) 1.09 (1.07–1.12) 1.00
With Stroke Without Stroke
Smokers Non-smokers Smokers Non-smokers
Group HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Referent
Unadjusted 1.41 (1.37–1.46) 1.54 (1.52–1.55) 0.96 (0.95–0.98) 1.00
Demographic-adjustedb 1.53 (1.49–1.58) 1.32 (1.31–1.33) 1.25 (1.24–1.27) 1.00
Adjusted for all covariatesc 1.22 (1.19–1.25) 1.18 (1.17–1.20) 1.08 (1.06–1.10) 1.00
With Peripheral Arterial Disease Without Peripheral Arterial Disease
Smokers Non-smokers Smokers Non-smokers
Group HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Referent
Unadjusted 1.55 (1.52–1.59) 1.59 (1.57–1.60) 0.92 (0.91–0.93) 1.00
Demographic-adjustedb 1.56 (1.52–1.59) 1.33 (1.32–1.34) 1.23 (1.22–2.25) 1.00
Adjusted for all covariatesc 1.22 (1.18–1.26) 1.14 (1.13–1.16) 1.07 (1.05–1.10) 1.00
aHazards Ratio (HR) and 95 % confidence interval
bDemographic variables of age, gender and race
cFinal multivariable model adjusted for demographic characteristics (age, sex and race), clinical conditions (diabetes, hypertension, coronary disease, peripheral
vascular disease, cerebrovascular disease, heart failure, pulmonary disease, cancer, AIDS, body mass index), lifestyle and functional factors (difficulty in walking
and transfers, alcohol use), socioeconomic factors (employment status), erythropoietin use pre-dialysis, and laboratory factors (serum albumin, eGFR at dialysis
initiation). Note the atherosclerotic condition was not included in the adjusted analysis, if it was the primary stratifying variable
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transplantation [26]. Not only did we confirm their ob-
servations, we provide further evidence that the nega-
tive impact of smoking is substantial, worse among
those with atherosclerotic disease, and extends to al-
most all demographic groups and did not abate
following multivariable adjustment. The impact of
smoking on kidney transplant rates among young adult
smokers with atherosclerotic disease is noteworthy and
concerning given that young patients are generally
considered to have the greatest opportunity of
Fig. 1 Hazard Ratios for Death for groups stratified by Coronary Disease, smoking status and age. P value for each group versus referent (no
disease, non-smoker), **P < 0.001. Model adjusted for demographic characteristics (sex and race), clinical conditions (diabetes, hypertension,
peripheral vascular disease, cerebrovascular disease, heart failure, pulmonary disease, cancer, AIDS, body mass index), lifestyle and functional factors
(difficulty in walking and transfers, alcohol use, and employment status), erythropoietin use pre-dialysis, and laboratory factors (serum albumin, eGFR at
dialysis initiation). Age was modeled in quintiles
Fig. 2 Hazard Ratios for Death for groups stratified by Stroke, smoking status and age. P value for each group versus referent (no disease, non-smoker),
**P < 0.001. P value for each group versus referent (no disease, non-smoker), **P < 0.001. Model adjusted for demographic characteristics (sex and race),
clinical conditions (diabetes, hypertension, peripheral vascular disease, coronary disease, heart failure, pulmonary disease, cancer, AIDS, body mass
index), lifestyle and functional factors (difficulty in walking and transfers, alcohol use, and employment status), erythropoietin use pre-dialysis, and
laboratory factors (serum albumin, eGFR at dialysis initiation). Age was modeled in quintiles
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receiving a kidney transplant. For example, the rates of
kidney transplantation among young men with coron-
ary disease were reduced from 88 to 45 per 1000
person-years of follow up and similar patterns were
observed for men with stroke and peripheral arterial
disease. These data provide further compelling evi-
dence that smoking is associated with reduced kidney
transplantation rates among those who may benefit
most.
There are limited studies in the literature that have ex-
plored the relationship of smoking with clinical out-
comes among incident dialysis cohorts. While, previous
studies have demonstrated that smoking is associated
with adverse clinical outcomes, most of these have con-
sidered smoking as an adjustment variable rather than
the primary exposure [10–15]. Furthermore, to our
knowledge, only a single published study has explored
risks of smoking among dialysis patients with pre-
existing atherosclerotic disease [10].
The current body of evidence would suggest that
tobacco use is an independent predictor of all-cause
and infection-related mortality [11, 13–15] and de-
novo vascular disease [10]. However, it has been
unclear until now the extent to which smoking con-
tributes to death and transplantation in men and in
women with atherosclerotic disease and across differ-
ent age categories. Defining the magnitude and extent
of these risks provides further compelling evidence to
physicians, professional bodies and to policy makers
that smoking is detrimental to all patients following
dialysis initiation.
This observational study is not without limitations.
The classification of smoker status was based on the
Medical Evidence record at dialysis initiation, which
may underreport this behavior [27]. Misclassification
bias would tend to underestimate the true magnitude
of exposure-outcome associations. Furthermore, our
analysis did not capture the number of cigarettes
smoked or pack-years and consequently we were un-
able to assess the duration of exposure or a gradient
effect. We submit, however, that the present study is
no substitute for well-designed prospective studies
that could accurately confirm smoking status, and
categorize the duration and pack years. We also
recognize the limitations of observational studies in
identifying cause and effect associations. Despite these
limitations, this study had several strengths that are
worthy of mention. Its large sample size and the rep-
resentativeness of the US dialysis population allow ex-
cellent generalizability to all age and sex subgroups.
The US registry captured information on a large
number of demographic, clinical, laboratory and life-
style characteristics, which facilitated a comprehensive
adjustment for confounding as well as the opportunity
to explore effect sizes in men and in women and
cross all age groups.
Fig. 3 Hazard Ratios for Death for groups stratified by Peripheral Arterial Disease, smoking status and age. P value for each group versus referent
(no disease, non-smoker), **P < 0.001. P value for each group versus referent (no disease, non-smoker), **P < 0.001. Model adjusted for demographic
characteristics (sex and race), clinical conditions (diabetes, hypertension, coronary disease, cerebrovascular disease, heart failure, pulmonary disease,
cancer, AIDS, body mass index), lifestyle and functional factors (difficulty in walking and transfers, alcohol use, and employment status), erythropoietin
use pre-dialysis, and laboratory factors (serum albumin, eGFR at dialysis initiation). Age was modeled in quintiles
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Conclusions
The present study highlights the detrimental effect of
smoking on the risk of death and kidney transplant-
ation among new patients with and without pre-
existing atherosclerotic conditions. Smoking contrib-
uted significantly to higher death rates and lower rates
of kidney transplantation for men and women of all
ages. These risks were substantial, greatest for younger
patients, and largely independent of known mortality
predictors. Although, it might be expected that smokers
would do worse, the magnitude of the impact was far
greater than we anticipated especially among younger
patients. This study highlights the need for greater rec-
ognition of smoking as a mortality risk factor and risk
amplifier for adverse outcomes for patients who require
dialysis. Our study reaffirms a key message for all
healthcare providers that smoking cessation strategies
should be relentlessly pursued in all patients across the
spectrum of CKD including those who reach end-stage
kidney disease.
Additional files
Additional file 1: Table S1. Factors associated with the presence of
Smoking at dialysis onset among new Dialysis Patients1. Multivariable
analyses of factors associated with smoking at dialysis initiation. Model
included demographic, clinical, biochemical, lifestyle, employment and
functional status indicators measured at dialysis onset. C-statistic 78 %, 2
95 % confidence intervals. (DOC 59 kb)
Additional file 2: Figure S1a-c. Age-specific mortality rates for Coronary
disease, Peripheral Arterial Disease and Stroke for Men by smoking status.
P–value for differences between smokers and non-smokers **P < 0.01,
*P < 0.05. (ZIP 665 kb)
Additional file 3: Figure S2a-c. Age-specific mortality rates for Coronary
disease, Peripheral Arterial Disease and Stroke for Women by smoking
status. P–value for differences between smokers and non-smokers
**P < 0.01, *P < 0.05. (ZIP 642 kb)
Additional file 4: Figure S3a-c. Age-specific transplantation rates for
Coronary disease, Peripheral Arterial Disease and Stroke for Men by smoking
status. P–value for differences between smokers and non-smokers
**P < 0.01, *P < 0.05. (ZIP 586 kb)
Additional file 5: Figure S4a-c. Age-specific transplantation rates for
Coronary disease, Peripheral Arterial Disease and Stroke for Women by
smoking status. P–value for differences between smokers and non-smokers
**P < 0.01, *P < 0.05. (ZIP 582 kb)
Table 4 Hazards Ratios (HR) for Kidney Transplantation for each Atherosclerotic Condition by Smoking Status among new dialysis
Patientsa
With Coronary Disease Without Coronary Disease
Group Smokers Non-smokers Smokers Non-smokers
HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Referent
Unadjusted 0.31 (0.28–0.34) 0.35 (0.34–0.36) 0.78 (0.76–0.81) 1.00
Demographic-adjustedb 0.36 (0.33–0.40) 0.59 (0.57–0.61) 0.60 (0.57–0.62) 1.00
Adjusted for all covariatesc 0.61 (0.53–0.69) 0.76 (0.73–0.79) 0.74 (0.70–0.78) 1.00
With Stroke Without Stroke
Smokers Non-smokers Smokers Non-smokers
HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Referent
Unadjusted 0.31 (0.26–0.36) 0.31 (0.30–0.33) 0.79 (0.76–0.82) 1.00
Demographic-adjustedb 0.34 (0.29–0.40) 0.50 (0.48–0.52) 0.59 (0.57–0.61) 1.00
Adjusted for all covariatesc 0.50 (0.40–0.63) 0.64 (0.59–0.68) 0.75 (0.71–0.79) 1.00
With Peripheral Arterial Disease Without Peripheral Arterial Disease
Smokers Non-smokers Smokers Non-smokers
HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Referent
Unadjusted 0.32 (0.29–0.36) 0.32 (0.31–0.33) 0.81 (0.78–0.84) 1.00
Demographic-adjustedb 0.35 (0.31–0.39) 0.46 (0.44–0.48) 0.59 (0.57–0.62) 1.00
Adjusted for all covariatesc 0.57 (0.48–0.67) 0.66 (0.62–0.70) 0.74 (0.70–0.78) 1.00
aHazard Ratios for first kidney transplant (HR) and 95 % confidence intervals
bDemographic variables of age, gender and race
cFinal multivariable model adjusted for demographic characteristics (age, sex and race), clinical conditions (diabetes, hypertension, coronary disease, peripheral
vascular disease, cerebrovascular disease, heart failure, pulmonary disease, cancer, AIDS, body mass index), lifestyle and functional factors (difficulty in walking and
transfers, alcohol use), socioeconomic factors (employment status), erythropoietin use pre-dialysis, and laboratory factors (serum albumin, eGFR at dialysis initiation).
Note the atherosclerotic condition was not included in the adjusted analysis, if it was the primary stratifying variable
Stack et al. BMC Nephrology  (2016) 17:95 Page 10 of 12
Abbreviations
95 % CI, 95 % confidence intervals; AOR, Adjusted odds ratio; CKD-EPI,
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